Showing 20 of 72 recruiting trials for “primary-vitreoretinal-large-b-cell-lymphoma”
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy
RecruitingNCT06779435 ↗
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
👨⚕️ Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañón📍 15 sites📅 Started Nov 2024View details ↗
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
RecruitingNCT07335120 ↗
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
👨⚕️ qlr2007@126.com Qian, PhD, Navy General Hospital, Beijing📍 1 site📅 Started Aug 2024View details ↗
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
👨⚕️ QingQing Cai, MD. PhD., Sun yat-sen university cancer cente📍 2 sites📅 Started Aug 2024View details ↗
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
👨⚕️ Michael Dickinson, MBBS, D Med Sc, FRACP, FRCPA, Peter MacCallum Cancer Centre, Australia📍 6 sites📅 Started May 2024View details ↗
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →